Posted on November 16, 2014

The Department of Radiation Oncology in the National Center for Cancer Care and Research (NCCCR), part of Hamad Medical Corporation (HMC), recently announced the clinical introduction and successful launch of MR-Guided Focused Ultrasound (MR–g FUS) for the treatment of cancer that has metastasized (spread) to the bones.

HMC introduces MR-guided 1 [].jpgThe NCCCR is the first hospital in the GCC region and one of only seventeen centers globally with the capacity to perform these treatments under MRI guidance.

Dr. Noora Al Hammadi, Chairman of Radiation Oncology at the NCCCR, stated that this development would be of significant benefit to patients. “Bones are one of the most common areas to which cancer spreads. Metastases in the bone can affect nerve endings and, left untreated, can result in factures which significantly impact the patient’s quality of life. This is why this technique is so important. It reduces pain and minimizes the growth of bone tumors.”

Explaining how the treatment works, Dr. Al Hammadi said: “MR - Guided FUS is a non-invasive thermal ablation technique that enables the physician to perform localized ablation, or destruction, of the tumor tissue. This is done by focusing therapeutic ultrasound energy precisely and at the targeted volume. MR guidance allows real time monitoring of the location and the intensity of the rise in temperature at the site of treatment, allowing for careful localized treatment and monitoring of the therapeutic procedure.”

She added: “Clinical trials in patients with bone metastases have demonstrated that this is an effective tool for pain reduction and relief, and therefore a valuable addition to the treatment types available for our cancer patients.” The introduction of this new treatment was a team effort for HMC with the Department of Radiation Oncology working closely with the Departments of Anesthesia and Pain Management to develop and implement this important service. 

HMC introduces MR-guided 2 [].jpg

Qatar Airways HQ 728x90